Radioimmunoimaging of AL Amyloidosis
Radioimmunoimaging of AL Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive
 monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT
 imaging in patients with AL amyloidosis.
To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis
 without significant cardiac (New York Heart Association class IV) disease and not be on
 kidney dialysis. Additionally, after testing, their blood must not contain antibodies to
 mouse proteins. The study requires an intravenous infusion, given over 10 minutes, of the
 radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 to 7
 days after infusion of the antibody. A 5 ml blood specimen needs to be furnished 4 and 8
 weeks after the antibody infusion.
Inclusion Criteria:

 -  Confirmed diagnosis of AL amyloidosis

 Exclusion Criteria:

 -  New York Heart Association class IV

 -  patient on renal dialysis

 -  serum antibodies to mouse protein